NDLI: Adjuvante endokrine Therapie des Mammakarzinoms.

Please wait, while we are loading the content...

Adjuvante endokrine Therapie des Mammakarzinoms.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Huober, Jens Thürlimann, Beat
Description	Author Affiliation: Huober J ( Senologisches Zentrum Ostschweiz, Kantonsspital St. Gallen, St. Gallen. Jens.huober@kssg.ch)
Abstract	Tamoxifen is the standard treatment in premenopausal hormone-receptor positive breast cancer patients with additional benefit in some of these women by adding ovarian ablation or suppression. Actual trials are investigating the use of more complete estradiol suppression with an LHRH agonist in combination with an aromatase inhibitor (TEXT, SOFT and ABCSG 12 trial) in premenopausal patients. Outside clinical trials this treatment may be considered in special cases when tamoxifen is contraindicated. In the majority of postmenopausal women the optimal adjuvant hormonal therapy includes the use of an aromatase inhibitor. However the best use of these agents, either as initial therapy or after treatment with tamoxifen has still to be answered. Again the optimal duration of endocrine therapy remains still open. Extended adjuvant therapy with an AI after completion of five years tamoxifen is especially in node positive patients a reasonable option. However if extension of endocrine therapy with an AI after five years of an AI-containing regimen is also beneficial is currently investigated in several clinical trials. In selected postmenopausal patients with hormone-receptor positive disease the use of five years of tamoxifen can still be a viable option.
File Format	HTM / HTML
ISSN	00405930
Issue Number	4
Volume Number	65
e-ISSN	16642864
Journal	Therapeutische Umschau
Language	German
Publisher	Hogrefe Verlag
Publisher Date	2008-04-01
Publisher Place	Switzerland
Access Restriction	Subscribed
Subject Keyword	Discipline Therapeutics Antineoplastic Agents, Hormonal Therapeutic Use Breast Neoplasms Drug Therapy Neoplasms, Hormone-dependent Adverse Effects Antineoplastic Combined Chemotherapy Protocols Aromatase Inhibitors Chemotherapy, Adjuvant Gonadotropin-releasing Hormone Analogs & Derivatives Humans Prognosis Randomized Controlled Trials As Topic Tamoxifen English Abstract Journal Article Review
Alternative Title	Adjuvant endocrine therapy in breast cancer
Content Type	Text
Resource Type	Article
Subject	Medicine

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Are we ready to change clinical practice after the 'soft and text' results?

Preoperative medical therapy before surgery for uterine fibroids

Adjuvant hormonal therapy and fertility preservation in premenopausal breast cancer: a survey among Italian oncologists.

Chemotherapy for advanced prostate cancer

Aktuelle Therapie des fortgeschrittenen Prostatakarzinoms.

Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer.

Adjuvant endocrine therapy for premenopausal women with breast cancer.

Extending Adjuvant Aromatase-Inhibitor Therapy to 10 Years.

Therapie des rektumkarzinoms.

Adjuvante endokrine Therapie des Mammakarzinoms.

Similar Documents

Are we ready to change clinical practice after the 'soft and text' results?

Preoperative medical therapy before surgery for uterine fibroids

Adjuvant hormonal therapy and fertility preservation in premenopausal breast cancer: a survey among Italian oncologists.

Chemotherapy for advanced prostate cancer

Aktuelle Therapie des fortgeschrittenen Prostatakarzinoms.

Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer.

Adjuvant endocrine therapy for premenopausal women with breast cancer.

Extending Adjuvant Aromatase-Inhibitor Therapy to 10 Years.

Therapie des rektumkarzinoms.

Adjuvante endokrine Therapie des Mammakarzinoms.